About the company:-

Lupin is a renowned pharma player having a wide range of quality, affordable generic
and branded formulations and APIs. The company, which was named after the Lupin
flower, commenced its business in 1968.
It has world class manufacturing facilities across India and Japan that have played a
critical role in enabling the company realise its global aspirations. Benchmarked to
international standards, Lupin’s facilities are approved by international regulatory
agencies such as US FDA, UK MHRA, Japan's MHLW, TGA Australia, WHO, and
the MCC South Africa.
The company first gained recognition when it became one of the world's largest
manufacturers of Tuberculosis (TB) drugs. Today, it has significant market share in
the cardiovascular, diabetology, asthma, paediatrics, CNS, anti-infective and NSAIDs
therapy segments.
Advanced market formulations comprised nearly 52 per cent of Lupin’s revenues in
FY 12. Its drugs and products reached over 100 countries in the world.
The company has emerged as the fifth largest and among the fastest-growing
companies in the US. The company's consolidated revenues and profit after tax were
Rs 94,616 million (US$ 1.55 billion) and Rs 13,142 million (US$ 216.05 million),
respectively, for FY 2012–13.
Mission/Vision
Lupin's mission is to become a transnational pharmaceutical company through the
development and introduction of a wide portfolio of branded and generic products in
key markets.

Our Vision
Lupin Pharmaceuticals, Inc. is committed to bringing innovative products for the
healthcare professional to improve the health and well-being of individuals.
Lupin Pharmaceuticals, Inc. is well positioned for growth in the US market. We can
capitalize on the strengths of our parent company, Lupin Limited:
 Scientific expertise to develop new and improved products and product line
extensions;
 Manufacturing technology, expertise and infrastructure;
 Financial resources.

SWOT Analysis
Strength Weakness

- Worldwide leader in Anti TB drugs - High dependence on global

- In the US and Japanese market it is formulation business with 84% revenue
the largest generic player. coming from US market.
- Wide global footprint as it is present - It operates in low growth segments
in over 70 countries such CNS, respiratory diseases

Threat Opportunities

- Price regulation by government - Increased health awareness

reduce the pricing ability of company.
- With around 20k unorganized and
300 large organized player makes
India Pharma industry highly
competitive
- Emerging technological trends in drug
delivery.
- Increasing prevalence of TB in
developing countries.
Lupin’s Business Model

Market –

Advance Markers – Exponential Growth

Geographical Expansion – Emerging Markets

Enhanced Market Penetration & New Therapies

Generics + Formulation + API = Sustainable Earnings, Accelerated Growth, Fulfilling Stakeholder

Aspiration

Alliances –

In-Licensing

Long term partnership with customers

Acquisitions –

Markets

Therapies

Technology